215 related articles for article (PubMed ID: 31996142)
1. Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
Cho HJ; Lim YJ; Kim J; Koh WJ; Song CH; Kang MW
BMC Infect Dis; 2020 Jan; 20(1):81. PubMed ID: 31996142
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
4. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA
Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820
[TBL] [Abstract][Full Text] [Related]
5. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
[TBL] [Abstract][Full Text] [Related]
6. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
[No Abstract] [Full Text] [Related]
7. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
[TBL] [Abstract][Full Text] [Related]
8. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.
Heyckendorf J; Olaru ID; Ruhwald M; Lange C
Am J Respir Crit Care Med; 2014 Aug; 190(4):374-83. PubMed ID: 24941306
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
10. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.
Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J
Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
13. [The changes and the significance of cellular immune function in peripheral blood of patients with multidrug-resistant and extensively drug-resistant pulmonary tuberculosis].
Yang Y; Tang SJ; Zhang Q; Sun H; Liu YD; Hao XH; Yao L; Gu J
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Feb; 34(2):109-13. PubMed ID: 21426728
[TBL] [Abstract][Full Text] [Related]
14. Drug Resistance Characteristics of
Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
[No Abstract] [Full Text] [Related]
15. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
16. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
[TBL] [Abstract][Full Text] [Related]
18. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
Fofana MO; Shrestha S; Knight GM; Cohen T; White RG; Cobelens F; Dowdy DW
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956422
[TBL] [Abstract][Full Text] [Related]
19. A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
Li Z; Liu F; Chen H; Han Y; You Y; Xie Y; Zhao Y; Tan J; Guo X; Cheng Y; Wang Y; Li J; Cheng M; Xia S; Niu X; Wei L; Wang W
J Glob Antimicrob Resist; 2022 Dec; 31():328-336. PubMed ID: 36210030
[TBL] [Abstract][Full Text] [Related]
20. Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Jiang H; Li X; Xing Z; Niu Q; Xu J
Curr Drug Deliv; 2023; 20(3):306-316. PubMed ID: 35546770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]